nabumetone has been researched along with Arthritis in 14 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
Arthritis: Acute or chronic inflammation of JOINTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nabumetone is biopharmaceutics classification system (BCS) class II drug, widely used in the treatment of osteoarthritis and rheumatoid arthritis." | 7.88 | Development of Microemulsion Based Nabumetone Transdermal Delivery for Treatment of Arthritis. ( Chabukswar, AR; Deore, GK; Jagdale, SC, 2018) |
| "Twenty patients (1 male, 19 females, mean age 62, range 45-86 years) with acute stage articular disorders (gonarthritis, coxarthritis, humero-scapular periarthritis) were treated for 10 days with 1 g nabumetone daily." | 7.68 | [Osteoarthritis and analgesic-antiphlogistic therapy. Preliminary report on the tolerability and efficacy of nabumetone treatment]. ( Menarini, C; Sartini, S; Vaiani, G; Zuffa, F, 1990) |
| " We studied 17 women with arthritis and hypertension who were receiving fosinopril and HCTZ, and administered sequentially in random order ibuprofen, sulindac, and nabumetone for 1 month each, with an intervening 2-week washout period between each treatment period." | 5.09 | Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. ( Cook, ME; Thakur, V; Wallin, JD, 1999) |
| " In an ongoing study of patients with osteo- or rheumatoid arthritis, currently in its fourth year, nabumetone has been shown to be relatively gastric sparing when compared with naproxen." | 5.06 | New understandings of NSAID gastropathy. ( Roth, SH, 1989) |
| "Safer treatment for arthritis can be achieved by combining misoprostol with traditional NSAIDs or by using one of two new agents, nabumetone or etodolac." | 4.80 | Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis. ( Bensen, W; Zizzo, A, 1998) |
| "Nabumetone is biopharmaceutics classification system (BCS) class II drug, widely used in the treatment of osteoarthritis and rheumatoid arthritis." | 3.88 | Development of Microemulsion Based Nabumetone Transdermal Delivery for Treatment of Arthritis. ( Chabukswar, AR; Deore, GK; Jagdale, SC, 2018) |
| "Nabumetone is a new non-steroidal anti-inflammatory drug advocated for use in the symptomatic treatment of rheumatic and inflammatory conditions." | 3.76 | Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases. ( Friedel, HA; Todd, PA, 1988) |
| "A postmarketing surveillance project monitoring the adverse effect profile of the NSAID, nabumetone, was performed in 10,800 patients with osteoarthritis or rheumatoid arthritis, recruited by general practitioners in the UK." | 3.68 | A 12-month postmarketing surveillance study of nabumetone. A preliminary report. ( Jenner, PN, 1990) |
| "Twenty patients (1 male, 19 females, mean age 62, range 45-86 years) with acute stage articular disorders (gonarthritis, coxarthritis, humero-scapular periarthritis) were treated for 10 days with 1 g nabumetone daily." | 3.68 | [Osteoarthritis and analgesic-antiphlogistic therapy. Preliminary report on the tolerability and efficacy of nabumetone treatment]. ( Menarini, C; Sartini, S; Vaiani, G; Zuffa, F, 1990) |
| " When the possibility of poor compliance and the potential adverse effects of misoprostol are considered, rebamipide appears to be a clinically effective and safe alternative." | 2.79 | Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. ( Cho, CS; Kang, YM; Kim, JH; Kim, SK; Lee, DH; Lee, SK; Lee, ST; Lee, YC; Park, SH; Park, W; Park, YW; Rew, JS; Yoo, WH, 2014) |
| "Nabumetone is a novel nonacidic nonsteroidal anti-inflammatory drug (NSAID) developed by Beecham Pharmaceuticals." | 1.27 | Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology. ( Flack, JD; Jackson, D; Mangan, FR, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 8 (57.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jagdale, SC | 1 |
| Deore, GK | 1 |
| Chabukswar, AR | 1 |
| Kim, JH | 1 |
| Park, SH | 1 |
| Cho, CS | 1 |
| Lee, ST | 1 |
| Yoo, WH | 1 |
| Kim, SK | 1 |
| Kang, YM | 1 |
| Rew, JS | 1 |
| Park, YW | 1 |
| Lee, SK | 1 |
| Lee, YC | 1 |
| Park, W | 1 |
| Lee, DH | 1 |
| Lems, WF | 1 |
| van Berge Henegouwen, GP | 1 |
| Bijlsma, JW | 1 |
| Bensen, W | 1 |
| Zizzo, A | 1 |
| Magro, CM | 1 |
| Crowson, AN | 1 |
| Thakur, V | 1 |
| Cook, ME | 1 |
| Wallin, JD | 1 |
| Freston, JW | 1 |
| Jenner, PN | 1 |
| Sartini, S | 1 |
| Zuffa, F | 1 |
| Menarini, C | 1 |
| Vaiani, G | 2 |
| Grossi, E | 1 |
| Roth, SH | 1 |
| Friedel, HA | 1 |
| Todd, PA | 1 |
| Mangan, FR | 1 |
| Flack, JD | 1 |
| Jackson, D | 1 |
5 reviews available for nabumetone and Arthritis
| Article | Year |
|---|---|
['Stomach-friendly' NSAIDs: careful optimism?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Gastritis; Humans; Ibuprofen; Misopro | 1995 |
Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Butanones; Drug Therapy, Comb | 1998 |
Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Cyclooxygenase 1; Cyclooxygenase 2; C | 1999 |
Meta-analysis of Italian clinical trials of nabumetone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Buta | 1990 |
Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; | 1988 |
5 trials available for nabumetone and Arthritis
| Article | Year |
|---|---|
Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity.
Topics: Adult; Aged; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Butanon | 2014 |
Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs.
Topics: Acetaminophen; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Ar | 1999 |
Meta-analysis of Italian clinical trials of nabumetone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Buta | 1990 |
New understandings of NSAID gastropathy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Clinical Trials as Topic | 1989 |
Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; | 1988 |
6 other studies available for nabumetone and Arthritis
| Article | Year |
|---|---|
Development of Microemulsion Based Nabumetone Transdermal Delivery for Treatment of Arthritis.
Topics: Administration, Cutaneous; Animals; Arthritis; Butanones; Drug Delivery Systems; Drug Liberation; Em | 2018 |
Pseudoporphyria associated with Relafen therapy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Connective Tissue Diseas | 1999 |
[Side effects cause enormous costs. Expensive arthritis therapy].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Celecoxib; | 2001 |
A 12-month postmarketing surveillance study of nabumetone. A preliminary report.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Female; Foll | 1990 |
[Osteoarthritis and analgesic-antiphlogistic therapy. Preliminary report on the tolerability and efficacy of nabumetone treatment].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Drug Evaluat | 1990 |
Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology.
Topics: Age Factors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Biological Availability; B | 1987 |